StreetInsider.com News Articles

Eledon phase 2 data shows tegoprubart outperforms tacrolimus in QoL

Mon, 26 Oct 2026 07:00:17 -0400

Eledon Pharmaceuticals (Nasdaq: ELDN) presented patient-reported outcomes data from its Phase 2 BESTOW clinical trial at the American Society of Nephrology Kidney Week 2026 Annual Meeting, held October 21-25 in Denver, Colorado.

The data compared tegoprubart, an investigational immunosuppression therapy, against tacrolimus, the current standard of care, in kidney transplant recipients over 12 months. Results were assessed using two validated measures: the Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) and the Kidney Disease Quality of Life Short Form (KDQOL-SF) Symptoms and Problems Scale.

On the MTSOSD-59R scale, tegoprubart-treated patients reported continued reductions in symptom occurrence from baseline at months 6

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology

Mon, 26 Oct 2026 07:00:00 -0400

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence

Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus

Results further validate the differentiated clinical profile of tegoprubart and potential to transform standard of care in kidney transplantation

IRVINE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new positive patient-reported outcomes data from the Phase 2

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology

Mon, 26 Oct 2026 07:00:00 -0400

Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus

Results further validate the differentiated clinical profile of tegoprubart and potential to transform standard of care in kidney transplantation

IRVINE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new positive patient-reported outcomes data from the Phase 2

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Mon, 05 Oct 2026 16:05:00 -0400

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.

Details of the presentation are below:

Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients

Presenter: Andrew B. Adams,

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Mon, 05 Oct 2026 16:05:00 -0400

Details of the presentation are below:

Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients

Presenter: Andrew B. Adams,

Eledon's tegoprubart shows kidney function edge over tacrolimus at 24 months

Tue, 22 Sep 2026 07:00:16 -0400

Eledon Pharmaceuticals (Nasdaq: ELDN) presented updated data from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society in Sydney, Australia, on Sept. 22, 2026, showing that patients treated with tegoprubart maintained statistically significantly higher kidney function through 24 months compared with those treated with tacrolimus.

According to data from the study, tegoprubart-treated patients showed a mean estimated glomerular filtration rate (eGFR) of 71 mL/min/1.73 m² at month 24, compared with 58 mL/min/1.73 m² in the tacrolimus arm, a difference of approximately 13 mL/min/1.73 m². The difference was statistically significant at months 18, 21, and 24.

As of

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Tue, 22 Sep 2026 07:00:00 -0400

Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24

No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm

Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation

Phase 3 LEGACY study expected to initiate in the fourth quarter of 2026

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc.

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Tue, 22 Sep 2026 07:00:00 -0400

No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm

Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation

Phase 3 LEGACY study expected to initiate in the fourth quarter of 2026

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Wed, 09 Sep 2026 07:00:00 -0400

IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026.

Details of the presentation are below:

Oral Presentation

Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evaluating the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection

Presenter: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Wed, 09 Sep 2026 07:00:00 -0400

Details of the presentation are below:

Oral Presentation

Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evaluating the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection

Presenter: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief

Eledon files IND for islet cell trial, eyes Phase 3 kidney study

Thu, 03 Sep 2026 07:01:04 -0400

Eledon Pharmaceuticals (Nasdaq: ELDN) announced several clinical development milestones for its investigational drug tegoprubart, an anti-CD40L antibody, across kidney and islet cell transplantation programs, according to a company statement.

The Irvine, California-based company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for a planned registrational clinical trial evaluating tegoprubart in type 1 diabetes patients undergoing pancreatic islet cell transplantation.

The company also reported that the first patients have been enrolled in an investigator-initiated study at the University of Chicago Medicine Transplant Institute evaluating a calcineurin inhibitor-free, tegoprubart-based regimen in patients with type 1 diabetes and chronic

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial

Thu, 03 Sep 2026 07:00:00 -0400

IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes

First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant

First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction

First patients dosed under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant

Company on

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial

Thu, 03 Sep 2026 07:00:00 -0400

IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes

First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant

First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction

First patients dosed under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant

Company on

Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c

Thu, 13 Aug 2026 16:41:20 -0400

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) reported Q2 EPS of ($0.27), $0.12 worse than the analyst estimate of ($0.15).
For earnings history and earnings-related data on Eledon Pharmaceuticals, Inc. (ELDN) click here.

Form 10-Q Eledon Pharmaceuticals, For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260813/26921885.html

Form 10-Q Eledon Pharmaceuticals, For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260813/26921885.html

Form 8-K Eledon Pharmaceuticals, For: Aug 13

Thu, 13 Aug 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260813/26921039.html

Form 8-K Eledon Pharmaceuticals, For: Aug 13

Thu, 13 Aug 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260813/26921039.html

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026

Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus

Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetes

Cash, cash equivalents and short-term investments of $88.8 million as of June 30, 2026

IRVINE, Calif., Aug. 13, 2026

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026

Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus

Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetes

Cash, cash equivalents and short-term investments of $88.8 million as of June 30, 2026

IRVINE, Calif., Aug. 13, 2026

Form 4 Eledon Pharmaceuticals, For: Jul 31 Filed by: Gros David-Alexandre C

Tue, 04 Aug 2026 17:23:00 -0400
si-local-file:///var/storage/secattach/20260804/26868073.html

Form 4 Eledon Pharmaceuticals, For: Jul 31 Filed by: Gros David-Alexandre C

Tue, 04 Aug 2026 17:23:00 -0400
si-local-file:///var/storage/secattach/20260804/26868073.html

Form 4 Eledon Pharmaceuticals, For: Jul 31 Filed by: Perrin Steven

Tue, 04 Aug 2026 17:22:00 -0400
si-local-file:///var/storage/secattach/20260804/26868061.html

Form 4 Eledon Pharmaceuticals, For: Jul 31 Filed by: Perrin Steven

Tue, 04 Aug 2026 17:22:00 -0400
si-local-file:///var/storage/secattach/20260804/26868061.html

Form SCHEDULE 13G Eledon Pharmaceuticals, Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:17:00 -0400
si-local-file:///var/storage/secattach/20260731/26848163.html